Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 5/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.35 |
| ▸ | THRA | P10827 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 4/20 | 0.34 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.34 |
| ▸ | NQO2 | P16083 | 2/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.34 |
| ▸ | F13A1 | P00488 | 1/20 | 0.34 |
| ▸ | TGM1 | P22735 | 1/20 | 0.34 |
| ▸ | STS | P08842 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29370014 | 0.97 | TGM2 (0.38) | TGM2MTNR1ACNR1CNR2EGFR | |
| SCHEMBL28997071 | 0.94 | TGM2 (0.40) | TGM2MTNR1ACNR1CNR2EGFR | |
| SCHEMBL28997008 | 0.89 | MTNR1A (0.39) | TGM2MTNR1AEGFRKCNA5THRA | |
| SCHEMBL28997061 | 0.87 | TGM2 (0.44) | TGM2MTNR1ACNR1CNR2BRD4 | |
| SCHEMBL28996998 | 0.86 | MTNR1A (0.38) | TGM2MTNR1AEGFRKCNA5THRA | |
| SCHEMBL28997012 | 0.78 | MTNR1A (0.40) | TGM2MTNR1AEGFRKCNA5THRA | |
| SCHEMBL28996992 | 0.77 | TGM2 (0.40) | TGM2MTNR1ACNR1CNR2BRD4 | |
| SCHEMBL26124919 | 0.77 | TGM2 (0.40) | TGM2MTNR1ACNR1CNR2BRD4 | |
| SCHEMBL28997537 | 0.76 | TGM2 (0.53) | TGM2 | |
| SCHEMBL28996914 | 0.76 | TGM2 (0.53) | TGM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116057042-A | Acrylamide-substituted indane compounds and their therapeutic uses | 赛诺菲 | 2023-05-02 | — | — | CN | claimed |
| US-20230265047-A1 | Acrylamide-Substituted Indane Compounds and Therapeutic Use Thereof | SANOFI (FR) | 2023-08-24 | — | — | US | disclosed |
| CN-116057042-A | Acrylamide-substituted indane compounds and their therapeutic uses | 赛诺菲 | 2023-05-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265047-A1 | Acrylamide-Substituted Indane Compounds and Therapeutic Use Thereof | IDH2, INA, IDH3A | TGM2 1405/4885MTNR1A 772/4885CNR1 1208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.